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Several signalling proteins involved in cell growth and diﬀerentiation represent attractive candidate targets for cancer diagnosis
and/or therapy since they can act as oncogenes. Because of their high speciﬁcity and low immunogeneicity, using artiﬁcial small
noncoding RNA (ncRNAs) as therapeutics has recently become a highly promising and rapidly expanding ﬁeld of interest. Indeed,
ncRNAs may either interfere with RNA transcription, stability, translation or directly hamper the function of the targets by bind-
ing to their surface. The recent ﬁnding that the expression of several genes is under the control of small single-stranded regulatory
RNAs, including miRNAs, makes these genes as appropriate targets for ncRNA gene silencing. Furthermore, another class of small
ncRNA, aptamers, act as high-aﬃnity ligands and potential antagonists of disease-associated proteins. We will review here the
recent and innovative methods that have been developed and the possible applications of ncRNAs as inhibitors or tracers in cancer
medicine.
Copyright © 2006 L. Cerchia and V. De Franciscis. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
INTRODUCTION
The accumulation of multiple genetic alterations that af-
fect the activity and/or expression of key proteins confers
the proliferative and invasive characteristics of growth to
cancer cells. Chromosomal deletions, rearrangements, and
gene mutations are selected during cancer progression be-
cause these defect(s) lead to altered protein signalling net-
works and generate a survival advantage for the cancer cell
[1].
The sequencing of the human genome, coupled to the
availability of novel techniques as the high throughput
screens and microarrays analysis, in less than a decade, has
led to a vast accumulation of information about genes that
are aberrantly regulated in cancers and has generated the re-
alistic hope of identifying, at the molecular level, the funda-
mental processes that cause transformation from normal cell
growth to malignancy.
Theimplicationsofthisknowledgeareprofoundbecause
adetailedunderstandingofthecomplexinteractionsthatoc-
cur at the genetic and protein levels provides attractive tar-
gets for rationally designing new drugs for new prevention
and treatment approaches. Indeed, a major challenge of can-
cer research studies is to distinguish individuals at high risk
of developing cancer thus to develop improved strategies for
earlier diagnosis and more eﬀective treatment with minimal
side eﬀects.
In the recent few years the increasing understanding on
the function of small noncoding RNAs (ncRNAs) has as
well generated a great enthusiasm because these molecules
m a yp r o v i d ea no b v i o u sp o t e n t i a lu s ea sp o w e r f u ln e wt o o l s
in cancer medicine. Under the deﬁnition of ncRNAs falls
a broad range of regulatory RNA molecules, such as ri-
bozymes,antisense,interferingsmallRNAsoraptamers,that
are either naturally found in several cell types or are artiﬁ-
cially designed to target gene expression or protein function
(Figure 1). The advantage of these biomolecules over other
biochemical or chemical substances employed up to now in-
clude high potency and speciﬁcity for the target, use of in
vitro techniques for their production, that considerably re-
duce production costs as well as the need for animal testing
andthatmarkedlyincreasespeciﬁcitiesandqualityassurance
in diagnostic and therapeutic applications.
In this review, we will examine recent work in the
possible applications of artiﬁcial small ncRNAs as versa-
tile biomolecules to identify and validate cancer targets and
as inhibitors or tracers in cancer medicine. The advantages
and drawbacks of the competing methodologies will be dis-
cussed here.
A HETEROGENEOUS FAMILY OF RNA-BASED TOOLS
Small noncoding RNAs elicit at least four distinct types of
responses that trigger speciﬁc gene inactivation, including2 Journal of Biomedicine and Biotechnology
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Figure 1: Schematic representation of the mode of action of ap-
tamers compared to other ncRNAs. Antisense, ribozymes, siRNAs,
miRNAs recognise the target nucleic acid by complementary base
pairingand,byactivatinganintracellularmolecularmachinery,im-
pair the expression of the corresponding protein. Aptamers act by
directly binding the target without interfering with its expression.
destruction of homologous mRNA, inhibition of translation,
de novo methylation of genomic regions that can block tran-
scription of target genes, and chromosomal rearrangement.
Among small RNAs, the microRNAs (miRNAs) are 21-
base-long RNA molecules that regulate gene expression. In
mammalians, miRNAs act by imperfectly base-pairing pre-
dominantly within the 3 u n t r a n s l a t e dr e g i o no ft a r g e tm e s -
senger RNAs and inhibiting protein translation [2]. Because
oftheirimportanceintheregulationofgeneexpressionmiR-
NAs have been implicated in the modulation of several phys-
iological and pathological cellular processes.
In RNA silencing mediated by siRNAs the sequence-
speciﬁc gene inhibition is initiated by small RNA duplexes
that cause the destruction of complementary target messen-
ger RNA.
Aptamers are single-stranded oligonucleotides whose in-
hibiting function relies on a completely diﬀerent mechanism
with respect to miRNA and siRNA. These molecules are gen-
erated by an in vitro evolutionary selection-ampliﬁcation
scheme, named SELEX (systematic evolution of ligands by
exponential enrichment) [3, 4]. Because they bind their tar-
get molecules at high aﬃnity and speciﬁcity, displaying dis-
sociation constants in the low picomolar to low nanomo-
lar range, aptamers are considered as attractive therapeutic
agents that rival antibodies.
As shown in Figure 2, the starting point for the genera-
tion of an aptamer is the synthesis of a nucleic acid library
(RNA, DNA, or modiﬁed RNA) of large sequence complex-
ity followed by the selection for oligonucleotides able to bind
with high aﬃnity and speciﬁcity to a target molecule. Ran-
domisation of a synthetic sequence stretch from 22 up to 100
nucleotidesinlengthhasbeenusedtocreateanenormousdi-
versity of possible sequences (4N diﬀerent molecules) which
in consequence generate a vast array of diﬀerent conforma-
tions with diﬀerent binding properties. The SELEX method
includes the following steps: (i) incubating the library with
the target molecule under conditions favourable for binding;
(ii) partitioning: molecules that, under the conditions em-
ployed, adopt conformations that permit binding to a spe-
ciﬁc target are then partitioned from other sequences; (iii)
dissociatingthenucleicacid-proteincomplexes;and(iv)am-
plifying of the nucleic acids pool to generate a library of re-
duced complexity enriched in sequences that bind to the tar-
get. This library will be then used as starting pool for the
next round of selection. After reiterating these steps for a
variable number of cycles, the resulting oligonucleotides are
subjected to DNA sequencing. The sequences correspond-
ing to the initially variable region of the library are screened
for conserved sequences and structural elements indicative
of potential binding sites and subsequently tested for their
ability to bind speciﬁcally to the target molecule. This selec-
tionschemeworkssincesingle-strandednucleicacidsfoldup
into unique 3D shapes in a similar manner to proteins, each
structure being unique and dictated by the sequence of the
nucleic acid.
By starting with 1015 random DNA sequences (thus, to a
ﬁrst approximation, 1015 speciﬁc shapes), it is possible to se-
lect (through 10–15 rounds of selection-ampliﬁcation) spe-
ciﬁc binding reagents for virtually each targeted human pro-
tein.
UNDERSTANDING THE MOLECULAR
MECHANISMS OF CANCER
Determininggenefunction
Determining by reverse genetics the function and the bio-
logical relevance of a given protein for a particular cancer
type is a critical step to validate the most promising molec-
ular targets for drug development. The possible strategies
that are usually used to understand the function of a spe-
ciﬁc gene in a cell are either based on techniques that impair
the expression of the candidate target gene or rely on the use
of products that act by speciﬁcally interfering or inhibiting
the function but not the expression of the ﬁnal product. In
both cases the resulting phenotype turns out as a powerful
source of information on the function of the target protein
(Figure 1).
(a) Gene silencing: the generation of null mutants by ho-
mologous recombination of a given gene in a cell or in an
entire organism has been extensively used to create models
of several human diseases, including cancer. Using this tech-
nique (named gene knockout), in which the gene of inter-
est is irreversibly disrupted and the synthesis of the encoded
products abolished, allowed to make an incredible and rapid
progress in our understanding of the function of several
oncogenes and tumor-suppressor genes. However, trigger-
ing gene silencing by homozygous gene ablation is laborious
and expensive and thus rather inappropriate for a large-scale
screening. An alternative strategy has been recently devel-
oped to determine the roles of particular genes in cancer that
is based on the use of ncRNAs for gene silencing. The RNA
interference (RNAi) has proven to be a precious approach
that permits loss-of-function phenotypic screens in mam-
malian somatic cells or in whole animals at high speciﬁcity.L. Cerchia and V. De Franciscis 3
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Figure 2: Schematic representation of the SELEX process. The single-stranded (ss) DNA library is ampliﬁed by polymerase chain reaction
(PCR) in order to generate the double-stranded DNA pool that will be transcribed by T7 RNA polymerase. The pool of RNA molecules with
diﬀerent conformations will be used for the selection process (see text for details).
Indeed, in the last few years the sequencing of the entire hu-
man genome coupled to advancements in high-throughput
oligonucleotide synthesis and better prediction of active se-
quencesisallowingthedesignofRNAiconstructsagainstvir-
tually any transcript. Furthermore, in contrast to the knock-
out approach, the RNA interference-based strategies achieve
loss of function phenotypes without the loss of genomic in-
formation of the targeted gene (recently reviewed in 5). This
leavesthepossibility torestoretheexactexpressionoftheen-
dogenous gene once the RNAi vector is silenced or removed.
(b) Functional inhibitors:am a j o rd r a w b a c kt og a i ni n -
formation on the function of a given protein by impairing
its expression is that proteins and enzymes involved in cru-
cial functions, such as cell growth and diﬀerentiation, fre-
quently act in concert with various partners thus forming
large stable complexes that dictate its function in the cell en-
vironment. Therefore, depleting a single key protein from
the cell will change, or even disrupt, at the same time one
or more of these multiprotein complexes. As a consequence,
the resulting phenotype will be produced by the simultane-
ous impairment of several protein functions and the under-
standing stays frequently ambiguous. Furthermore, silencing
a gene gives no information about which region of the puta-
tive target protein is important for its function.
To overcome these disadvantages, additional approaches
have been developed that enable to interfere with a given
protein function. Indeed, using monoclonal antibodies, pep-
tides, and small molecules to directly target the protein in
a drug-like manner has the advantage to interfere with the
protein activity without depleting the protein itself and thus
with low destabilisation of the proteomic status of the cell.
During the past decade, as excellent alternatives to these in-
hibitors, the RNA-based aptamers have proven to be highly
selective ligands and eﬃcient inhibitors of a wide variety of
proteins implicated in cancer. Aptamers have a larger sur-
face area as compared to small interfering compounds thus
presenting more points of contact with the target protein.
Furthermore, these molecules have been shown either to in-
hibit their target by competitive mechanisms or to interfere
with its conformation by noncompetitive mechanisms [6].
The ability to select aptamers directed against puriﬁed sol-
uble targets has recently incredibly progressed thanks to the
automation of part of the in vitro selection processes so that
several targets can be isolated in parallel strongly reducing
the time required for the selection. Aptamers for protein
targets of biomedical interest have been reported and many
of them are actually under clinical trials for cancer treat-
ment (Table 1). In particular, Food and Drug Administra-
tion has recently approved one aptamer developed by Eye-
tech (MacugenTM) that inhibits the human vascular en-
dothelial growth factor 165 (VEGF165), for the treatment
of age-related macular degeneration [7]. Since an obvious4 Journal of Biomedicine and Biotechnology
Table 1: Therapeutic aptamers in cancer treatment.
Aptamer Aptamer activity Therapeuticapplication
invitro invivo
Macugen Inhibition of VEGF165 Inhibition of the VEGF-induced
vascular permeability
Approved by FDA for treatment of age-related
macular degeneration
ProMune Agonist for toll-like
receptor 9 (TLR 9)
Activate the immune system
through TLR 9 against cancer
Phase 2: melanoma
Phase 1: renal cell carcinoma;
non- Hodgkin’s lymphoma; cutaneous T-cell
lymphoma, non-small-cell lung cancer
Agro 100 Binding to nucleolin
Antiproliferative activity in a broad Phase 1
Phase 2 launched in 2005
for advanced solid malignancies
array of tumor cell types; enhancement
of chemotherapeutic agents eﬀects
HYB2055 Agonist for TLR 9
Antitumor activity in nude mouse
Phase 2 for advanced solid malignancies xenografts with colon, breast,
lung cancer, and glioma cell lines
VaxImmune Agonist for TLR 9 Elicits a powerful immune response Phase 2 for several diﬀerent cancer indications
adjuvant against infectious disease and cancers
potential therapeutic use for aptamers to VEGF is in can-
c e r ,t h i sa p t a m e rw a st e s t e di nam o u s em o d e lo fn e p h r o b -
lastoma [8]. Renal histopathology revealed an 84% reduc-
tion in tumor weight in the aptamer-treated kidneys com-
pared to the controls. Furthermore, lung metastases were
seen in 20% of the aptamer-treated mice compared to 60%
of control animals. This same aptamer was also tested in a
murine model of neuroblastoma, where it resulted in 53%
r e d u c t i o ni nt u m o rg r o w t hc o m p a r e dt oc o n t r o l[ 9]. An-
other aptamer that inhibits receptor tyrosine kinase activa-
tion by binding to the corresponding ligand is the aptamer
against platelet-derived growth factor (PDGF). It has been
successfully used in vivo in animal models of cancer due to
itshighspeciﬁcityinthefactthatitsuppressesPDGFB-chain
(PDGF-BB) but not the epidermal- or ﬁbroblast-growth-
factor-2-induced proliferation [10]. Furthermore, the SE-
LEX methodology has been used to identify high-aﬃnity
2’-aminopyrimidine RNA ligands to the potent angiogenic
factor, the basic ﬁbroblast growth factor (bFGF). In cell
culture, these aptamers inhibited bFGF binding to both
low-aﬃnity sites and high-aﬃnity sites on FGF receptor-1
[11].
Even though several aptamers that inhibit receptor ty-
rosine kinases by binding to their soluble ligands have now
been selected, targeting the receptor itself that is a large in-
soluble glycosylated protein has only been recently addressed
[12]. To this aim we developed a general protocol of diﬀer-
ential whole-cell SELEX to target cell surface bound proteins
in their natural physiological environment. We have evolved
aptamers able to inhibit an active mutant of the receptor ty-
rosine kinase, Ret, by targeting its extracellular domain in
which such activating mutation is located. By this method,
the selection procedure was performed by using as target
the RETC634Y mutant expressed on PC12 cells. A library
of 2-ﬂuoro pyrimidine RNAs was incubated with parental
PC12 cells to remove aptamers that bind nonspeciﬁcally to
the cell surface. To select for aptamers that speciﬁcally bound
the mutant receptor, the supernatant was incubated with
PC12–RETC634Y cells. Unbound sequences were washed oﬀ,
the whole process reiterated 16 times, and the bound win-
ning sequences cloned. The resulting aptamers did not bind
to a recombinant EC C634Y RET fragment highlighting the
strength of the whole-cell approach. Among the selected ap-
tamers, the best inhibitor (D4) binds speciﬁcally to the Ret
receptortyrosinekinaseandblocksitsdownstreamsignalling
eﬀects on cell diﬀerentiation and transformation [12]. The
results suggest that the diﬀerential whole-cell SELEX ap-
proachwillbeusefulintheisolationofotherleadtherapeutic
compounds and diagnostic cell-surface markers. Aptamers
t h a th a v eh i g ha ﬃnity and speciﬁcity for tissues have also
been produced, demonstrating that complex targets, includ-
ing tumour tissue, are compatible with the SELEX process.
“Tissue SELEX” methodology could be favourable when the
precise molecular target is unknown but the target is, for ex-
ample, a speciﬁc type of cells. A ﬂuorescence based SELEX-
procedure was applied against transformed endothelial cells
asa complextarget todetectmicrovessels ofratexperimental
glioma, a fatal brain tumour which is highly vascularized. A
secondary selection scheme, named deconvolution-SELEX,
was carried out to facilitate the isolation of ligands for com-
ponents of interest within the targeted mixture. Other exam-
ples of proteins that have been reported as targets for devel-
opment of aptamers as promising therapeutics include the
tenascin-C, the Ras binding domain of Raf-1, the prostate
speciﬁc membrane antigen (PMSA), the protein kinase CβII,
the epidermal growth factor receptor-3 (ErbB3/HER3), and
the CXCL10 chemokine [13].
Identifying“cancergenes”
Two paradigmatic and elegant recent papers well demon-
strate the power of siRNAs in identifying new cancer targetsL. Cerchia and V. De Franciscis 5
involved in cell survival. Apoptosis-based anticancer ther-
apies are designed to achieve tumor eradication through
the use of death-inducing molecules. Because of its spe-
ciﬁc toxicity against transformed cells, the tumor necro-
sis factor (TNF)-related apoptosis-inducing ligand (TRAIL)
receptors are judged to be amongst the most promising
apoptosis-based antitumor targets. To better understand
the molecular mechanisms of TRAIL-induced apoptosis,
Aza-Blanc et al [14] carried out a large RNAi-based screen
to identify genes that modulate TRAIL-induced apoptosis.
They used an siRNA library to individually target 510 hu-
man genes (corresponding to 380 predicted kinases and 130
other predicted proteins) transfected in the cervical carci-
noma derived HeLa cell line. By using an assay that could
detect both sensitization and resistance to TRAIL-induced
apoptosis the authors identiﬁed a variety of genes that mod-
ulate both positively and negatively TRAIL activity. Further-
more, besides genes that encode well-characterised media-
tors of TRAIL, including the DR4 receptor for TRAIL and
the caspase 8 or known modulators of apoptosis (Myc and
JNK3), in the RNAi screen they detected and functionally
characterised two previously unknown genes, which were
found to modulate TRAIL-induced apoptosis. One of the
genes, DOBI (Downstream of Bid), is required for progres-
sion of the apoptotic signal through the intrinsic mitochon-
drial cell death pathway indicating that it may function to
mediate cytochrome c release induced by BID cleavage, the
other, named MIRSA (Mina53-related suppressor of apop-
tosis), is a gene that acts to prevent TRAIL-induced death.
Changes in the expression and/or activity of kinases and
phosphatases, key proteins of the cellular signalling path-
ways, are the most frequent molecular causes of cancer pro-
gression. MacKeigan et al [15] reported a large-scale RNAi
approach to identify kinases and phosphatases that regulate
cell survival and apoptosis. Authors transfected in HeLa cells
two large siRNA library sets against human kinase and phos-
phatase, containing two siRNAs for each target (correspond-
ing to 650 kinases and to 222 phosphatases). By the data ob-
tained they predicted that 11% of kinases and 32% of phos-
phatases are constituted of genes whose expression is critical
for cell survival. In addition to those for previously known
“survival kinases” (Akt2, KD2, SGK, PKCdelta) they identi-
ﬁed several genes with still unknown function, the silencing
of two of which resulted in a strong increase in apoptosis.
They also identiﬁed phosphatases that act as tumor suppres-
sorstosensitizeorpromoteapoptosis.Silencingofthese“cell
death phosphatases” resulted in marked cell protection to
chemotherapeutic-induced cell death. Furthermore, the au-
thors developed a further screen in the presence of low doses
ofchemotherapeuticsbywhichtheyidentiﬁedkinases whose
silencing increases the rate of apoptosis. The kinases identi-
ﬁed are thus promising targets for silencing in order to sensi-
tize the cancer cell to low doses of chemotherapeutic agents,
thus reducing unwanted side eﬀects in chemotherapy.
On the other hand, as alternative to transfection, siR-
NAs can be also expressed within the cells as a short hair-
pin RNA (shRNA) that is then processed by the cell machin-
ery to produce the small interfering double strand RNA. To
facilitate the use of RNAi as a genetic tool in mammals, Pad-
dison etal[16]andBe rnsetal[17]usedashRNAretrovirus-
based library approach to develop strategies that allow a high
throughput RNAi-based screen of mammalian genes. Berns
et al screened a library targeting around 8.000 human genes
for those that aﬀect the function of the tumour suppressor,
p53. Genes were subsequently identiﬁed by microarray de-
tectionoftheshRNAsequence[17].Paddisonandcolleagues
developed a shRNA library targeting around 10.000 human
and more than 5.0 0 0m o u s eg e n e s .T of a c i l i t a t et h eu s ei n
virtually any cell types, their shRNA expression library was
constructed in a vector that permits moving the shRNA en-
coding inserts to diﬀerent vectors by bacterial mating and
designed to function for both genetic selections and screens.
Indeed, for facilitating the screening, in addition to the selec-
tionpressurebothgroupsadoptedauniqueDNA“bar-code”
sequence present in the vector which can be identiﬁed us-
ing microarrays containing oligonucleotides corresponding
to the bar-code sequences.
The generation of large siRNA libraries has been further
improved by using, instead of shRNAs that are transcribed
by the RNA polymerase III, pri-miRNA based large tran-
scripts that permit to generate siRNAs driven by the RNA
polymerase II promoters that can be thus tightly regulated
both in culture and in vivo, in animal models [18, 19].
Two recent reports [20, 21]a d d r e s st h eu s eo fl a r g e
viral-based RNAi libraries to identify novel potential tumor-
suppressor genes thus further underscoring the power of
RNAi screening to understand the molecular mechanisms of
neoplastic transformation.
Kolfschoten et al [20] used a shRNA retrovirus-based li-
brary [17] in combination with in vitro neoplastic transfor-
mationassaystoscreenfornoveltumor-suppressorgenes.To
this aim they used a Ras-dependent transformation model of
genetically modiﬁed human primary BJ ﬁbroblast cells ex-
pressing the catalytic subunit of telomerase (hTERT), and
SV40 small T antigen (ST) in combination with the inhi-
bition of the expression of p53 and p16INK4A. In this cell
line the expression of the oncogenic H-RasV12 is suﬃcient
to confer anchorage-independence for survival and prolifer-
ation [22]. By this approach the authors identiﬁed few genes
whose silencing substitutes for the activity of the oncogenic
Ras one of which, the homeodomain transcription factor
PITX1, was not previously implicated as possible tumor sup-
pressor allowing anchorage-independent growth of ﬁbrob-
lasts. The authors showed that PITX1 regulates the Ras path-
way and thereby tumorigenesis. The mechanism appears to
involve constitutive activation of the Ras signalling pathways
at the level of GTP loading onto Ras itself. Indeed, PITX1 di-
rectly controls the expression of RASAL1, one of the negative
regulators of Ras belonging to the GTPase-activating protein
(GAP) family. The evidence that PITX1 is a tumor suppres-
sor was supported by the strong correlation between the low
PITX1 levels present in colon cancer cell lines and wt Ras ex-
pression and the low PITX1 expression levels in prostate and
bladder tumor tissues compared with normal tissues.
To identify genes that suppress oncogenic transforma-
tion, Wetsbrook et al [21] used genetically modiﬁed human6 Journal of Biomedicine and Biotechnology
epithelial mammarycellsthathavebeenimmortalized bythe
expression of hTERT and SV40 large T antigen and also nat-
u r a l l ye x p r e s sh i g hl e v e l so fM y c( T L M - H M E C s ) .F o r c e de x -
pression of an active mutant of PI3K confers to these cells
the ability to grow in an anchorage-independence manner
[23]. Based on the assumption that inactivation of a sin-
gle tumor-suppressor gene may be suﬃcient to shift TLM-
HMECs cells into a frankly transformed phenotype that can
be selected for, the authors used a shRNA retrovirus-based
library to infect TLM-HMECs [16]. In the screen they iden-
tiﬁed several potential suppressors of epithelial cell trans-
formation genes that represent potential tumor suppressors.
Most of them were associated with genes known to be in-
volved in key intracellular signalling pathways including Ras,
PI3K, and TGF-β signalling. In addition, they provided ev-
idence that one of these candidates, the transcriptional re-
pressor REST/NRSF, plays a previously unknown role in tu-
mor suppression. REST encodes a transcriptional factor in-
volved in repressing neuronal genes in non-neuronal cells.
Even though the mechanism by which REST silencing re-
leasesthetransformedstateshouldbestillelucidated,itlikely
involvesregulationofPI3K.Indeed, impairedRESTfunction
promoted epithelial cell transformation, enhanced the inten-
sity and duration of PI3K activity, eventually acting via the
transcriptional control of neurotrophins.
Despite the expanding potentiality of siRNAs the key
challenges for their development for gene silencing is largely
dependent on the improvement of siRNA speciﬁcity. Not ev-
ery sequence works, and a success rate of about one of three
should be expected. In addition, although the eﬀects are gen-
erally thought to be highly sequence speciﬁc, one potential
concern in using siRNAs for phenotypic screens is that the
observed eﬀects could be due to inhibition of either the in-
tended target or of an oﬀ-target mRNA [24]. Indeed, siRNAs
are not perfectly selective and results should be conﬁrmed
with an independent siRNA targeting of the same transcript
to understand whether or not some of the eﬀects see result
from an oﬀ-target transcript. Generation of libraries of mul-
tiple siRNAs for each gene has been therefore the most fre-
quent approach used to avoid this drawback and be safe to
conclude that the eﬀects are speciﬁc to the targeted gene.
DEFINING THE SIGNATURES OF CANCER CELLS:
MICRORNAs PROFILING
Early detection together with the accurate description of the
tumor type is crucial for a better diagnosis of cancer and a
more eﬀective therapy. Therefore, what is required to gain
an increased survival rate of the patient is the identiﬁcation
of multiple biomarkers that can be measured simultaneously
as a biological signature of the disease state. Using high-
throughput technologies allows the identiﬁcation of these
signatures and their validation by the rapid comparison of
samples from many diﬀerent patients with the realistic hope
of ﬁnding molecules that are informative of the type of can-
cer and with high predictive value for the patient.
The coordinated expression of speciﬁc miRNAs is be-
lieved to have a central role in diverse cellular processes,
including cell proliferation and apoptosis, and their altered
expression is involved in tumorigenesis. Indeed, expression
proﬁling of diﬀerential miRNA has been shown to represent
highly informative signatures for human cancers. Lu et al
[25] developed a bead-based technique coupled to ﬂow cy-
tometry to determine the expression proﬁles of 217 human
miRNAs in 332 cancer samples. They found that the expres-
sion pattern of a small set of miRNA dramatically varies
across tumour types, reﬂecting the lineage and diﬀerentia-
tionstatusofthetumor.Incontrast,proﬁlingexpressiondata
obtainedonthesamesamplesusing16,000mRNAswasinef-
fective, thus implicating miRNA proﬁling as highly informa-
tive to classify human cancer types [25]. Furthermore, their
resultsshowthattheexpressionpatternofasmallsetofmiR-
NAs is highly informative to classify human cancer types.
Furthermore,aswellillustratedbythethreefollowingre-
cent papers, the development of microarrays containing all
known miRNAs permitted to perform large-scale analysis of
miRNAexpressionproﬁlinginhumancancers.Intheﬁrstre-
port the authors [26] evaluated the activity of miRNA genes
in chronic lymphocytic leukemia (CLL) cells from 94 pa-
tients. Of the miRNA genes analysed, the researchers found
that the activity pattern of 13 of them accurately predicted
whether a person had the slow- or fast-progressing form of
CLL. They also identiﬁed a germ-line mutation in the miR-
16-1-miR-15 precursors, which caused low levels of miRNA
expression and thus may be considered as cancer susceptibil-
ity genes for CLL (see below). In a second paper, by apply-
ing a similar approach, the same group examined miRNA
expression proﬁle in 76 breast tumors compared to nor-
m a lb r e a s tt i s s u e[ 27]. In this study 29 miRNAs were sig-
niﬁcantly deregulated in breast cancer (either over-expressed
or downregulated). They found that miRNA expression was
correlated with breast tumors’ hormone status as well as its
metastatic, invasive, and proliferative potential. Most impor-
tant, their work demonstrated that the expression pattern of
as few as ﬁve miRNAs (miR-10b, miR-125b, miR-145, miR-
21, and miR-155) was suﬃciently informative to successfully
distinguish normal tissue from cancerous tissue. Finally, in
the paper by Huiling He et al [28] the researchers examined
samples of malignant tissue from 15 patients diagnosed with
papillary thyroid carcinoma and compared them with the
normal tissue adjacent to the tumors. They found 23 miR-
NAs that were signiﬁcantly altered in the cancerous tissue
when compared with the normal counterparts, with three of
them (miR-146, miR-221, and miR-222) dramatically over-
expressed, reaching 11-to-19-fold higher levels of expression
in the tumors. Further investigation revealed that the expres-
sion pattern of miR-146, miR-221, and miR-222 if combined
withthatoftwoadditionalmiRNAs(miR-21andmiR-181a),
formed a “signature” that clearly predicted the presence of
malignant tissue.
In conclusion, in several cancers the miRNA expression
proﬁles seem to be suﬃcient to provide a “signature” that is
directlyassociatedtotheclinicalstatusofthedisease.Indeed,
the utility of single markers in diagnosis and monitoring of
cancer is limited by the poor association of any single protein
withaspeciﬁcdiseaseorstageofdisease.ThusidentifyingtheL. Cerchia and V. De Franciscis 7
distinctive signature of a network of these regulatory signals
wouldenable us bya more precise diagnosis to detect tumors
earlier, at times when treatments are more eﬀective.
CANCER SIGNATURE MEASUREMENT
Developing methods that allow clinicians and researchers to
translate signature discoveries to routine clinical use by look-
ing simultaneously at a large number of biomarkers has now
become a major challenge in cancer diagnosis. Indeed, be-
cause they are readily accessible without any need of inva-
sive intervention measuring molecules expressed in serum or
plasma is highly preferable. However, many potential cancer
biomarkers in biological ﬂuids are present at low concentra-
tions, presumably in the low nanomolar range. Therefore,
the capability to measure multiple protein markers simul-
taneously depends on methods having not only low limits
of detection with elevated signals, but also coupled to very
low noise, thus capable to distinguish speciﬁc protein sig-
nalling in the presence of a huge excess of unrelated pro-
teins.
Theuseofaptamersasbiorecognitionelementforthede-
velopment of biosensors to detect protein targets oﬀers over
classical methods mainly based on antibodies, a lot of advan-
tages, such as the possibility of easily regenerate the immo-
bilised aptamers, their homogeneous preparation, and the
possibility of using diﬀerent detection methods due to easy
labelling [29]. Moreover, the enormous diversity of random
oligonucleotide libraries can exceed the diversity of antibod-
ies in the mammalian genome by several orders of magni-
tude.Since aptamersarenucleic acids,experience withDNA,
as in the production of DNA arrays, should be applicable to
the development of aptamer-based biosensors. On the other
side, the aptamer arrays can potentially expand the scope of
DNA microarrays to recognise expressed proteins as well as
expressed mRNAs. In this regard, numerous aptamers have
already been selected against a wide array of proteins, and
the possibility of acquiring aptamers against proteomes has
been advanced by automation of the in vitro selection pro-
cedure. These considerations explain why now the aptamer-
based technology for protein detection is in advanced stages
of development as useful tools in clinical diagnosis and ther-
apy. Furthermore, this technology has been improved by
the use of modiﬁed aptamer molecules, named photoap-
tamers by Petach et al at SomaLogic, Inc [30–33]. These
modiﬁedaptamers(eitherDNAorRNA)atspeciﬁclocations
include, in place of thymidine residues, the photoreactive 5-
bromodeoxyuridine (BrdU) that can form a speciﬁc cova-
lent crosslink with the target proteins. Indeed, short pulses
of ultraviolet light at 308nm induce a chemical crosslink be-
tween the BrdU residue and the electron rich amino acid on
the target protein that is in a speciﬁc location in proximity
and in the correctjuxtaposition of the BrdU. Since this cross-
linkingeventisdependentonthecorrectjuxtapositionofthe
BrdU and the target amino acid, it conveys speciﬁcity to the
photoaptamer-proteincomplex.Thisgivesrisetomultiplica-
tive speciﬁcity by a photochemical cross-link that follows the
initial aﬃnity binding event. Proteins captured on the array
are then measured either by universal protein staining or by
using speciﬁc antibodies.
In order to measure simultaneously large numbers of
proteins, even thousands, in biological ﬂuids multiple cap-
ture photoaptamers can be deposited and covalently linked
to the appropriate chip surface. Therefore, since photoap-
tamers covalently bind to their targets before staining, the
photoaptamer arrays can be vigorously washed to remove
backgroundproteins,thusprovidingtheneededpotentialfor
elevated signal-to-noise ratios.
The sensitivity and speciﬁcity of photoaptamers, com-
bined with the ability to automate and scale up their selec-
tion and the ability to use them on solid surfaces, indicate
that they could become an important factor in the develop-
ment of proteomic technology.
IN VIVO DELIVERING
Whether being used as experimental tools and/or pharma-
ceutical drugs, small ncRNAs need to be able to cross cell
membranes but negatively charged oligonucleotides will not
pass through a lipid layer such as cell membranes. Similar
to antisense oligonucleotides and ribozymes, the delivery of
synthetic siRNAs and aptamers can be improved via the use
of various delivery systems, which include synthetic carri-
ers, composed primary of lipids. Larger carriers such as lipo-
somes localise the drugs mainly to the blood compartment.
However, angiogenic blood vessels in most tissues have gaps
between adjacent endothelial cells large enough to cause the
extravagation of liposome/siRNA complexes into the tumor.
In addition, most solid tumors possess an enhanced vas-
cular permeability and impaired lymphatic drainage, which
leads to the accumulation of most liposomes within the tu-
mor tissues. For these reasons, a big eﬀort has recently been
devoted to develop delivery vehicles that can eﬃciently de-
liver these RNAs molecules in vivo for the success of these
molecules as therapeutics. Furthermore, the possibility to
chemically modify and easily engineer small RNAs permits
to express these molecules inside the target cell thus cou-
pling the advantages of drug-based to those of gene-based
therapy.
CONCLUDING REMARKS
Over the past few years the unexpected progress gathered in
the knowledge of the mode of action of small noncoding
RNAs is changing our point-of-view on the possible ap-
proaches to identify and to target tumor-associated genes.
These ﬂexible molecules have proven their enormous po-
tential both as diagnostic and therapeutic tools in several
ﬁelds of cancer medicine. Paradigmatic examples in the use
ofthesesmallRNAmoleculesincludethatofsiRNAsforhigh
selective gene silencing, aptamers as high aﬃnity inhibitory
ligands, the miRNA proﬁling for a more accurate description
of the tumor state, and the use of high sensitive aptamer-
based biosensors to readily measure the proteomic status in
biological ﬂuids. Therefore, developing ncRNAs as the new
generation of molecular tools for human health is an urgent8 Journal of Biomedicine and Biotechnology
challenge that in the next future should provide us with the
ability to tailor therapies to the cancer patient more eﬀec-
tively.
ACKNOWLEDGMENTS
This work was supported by the European Molecular Imag-
ing Laboratory (EMIL) Network (LSHC-2004-503569), and
by the MIUR-FIRB Grant (#RBIN04J4J7).
REFERENCES
[1] HanahanD,WeinbergRA.Thehallmarksofcancer.Cell. 2000;
100(1):57–70.
[2] BartelDP.MicroRNAs:genomics,biogenesis,mechanism,and
function. Cell. 2004;116(2):281–297.
[3] Ellington AD, Szostak JW. In vitro selection of RNA molecules
that bind speciﬁc ligands. Nature. 1990;346(6287):818–822.
[4] Tuerk C, Gold L. Systemic evolution of ligands by exponen-
tial enrichment: RNA ligands to bacteriophage T4 DNA poly-
merase. Science. 1990;249(4968):505–510.
[5] Dykxhoorn DM, Lieberman J. The silent revolution: RNA in-
terference as basic biology, research tool, and therapeutic. An-
nual Review of Medicine. 2005;56:401–423.
[6] LupoldSE,HickeBJ,LinY,CoﬀeyDS.Identiﬁcationandchar-
acterization of nuclease-stabilized RNA molecules that bind
human prostate cancer cells via the prostate-speciﬁc mem-
brane antigen. Cancer Research. 2002;62(14):4029–4033.
[7] Ruckman J, Green LS, Beeson J, et al. 2-ﬂuoropyrimidine
RNA-based aptamers to the 165-amino acid form of vascu-
lar endothelial growth factor (VEGF165): inhibition of recep-
tor binding and VEGF-induced vascular permeability through
interactions requiring the exon 7-encoded domain. Journal of
Biological Chemistry. 1998;273(32):20556–20567.
[8] HuangJ,MooreJ,SoﬀerS,etal.Highlyspeciﬁcantiangiogenic
therapy is eﬀective in suppressing growth of experimental
Wilms tumors. Journal of Pediatric Surgery. 2001;36(2):357–
361.
[9] Kim ES, Serur A, Huang J, et al. Potent VEGF blockade causes
regression of coopted vessels in a model of neuroblastoma.
Proceedings of the National Academy of Sciences of the United
States of America. 2002;99(17):11399–11404.
[10] Floege J, Ostendorf T, Janssen U, et al. Novel approach to spe-
ciﬁc growth factor inhibition in vivo: antagonism of platelet-
d e r i v e dg r o w t hf a c t o ri ng l o m e r u l o n e p h r i t i sb ya p t a m e r s .
American Journal of Pathology. 1999;154(1):169–179.
[11] Jellinek D, Green LS, Bell C, et al. Potent 2-amino-2-deox-
ypyrimidine RNA inhibitors of basic ﬁbroblast growth factor.
Biochemistry. 1995;34(36):11363–11372.
[12] CerchiaL,Ducong´ eF,PestourieC,etal.Neutralizingaptamers
from whole-cell SELEX inhibit the RET receptor tyrosine ki-
nase. PLoS Biology. 2005;3(4):697–704.
[13] Blank M, Weinschenk T, Priemer M, Schluesener H. System-
atic evolution of a DNA aptamer binding to rat brain tumor
microvessels: selective targeting of endothelial regulatory pro-
tein pigpen. Journal of Biological Chemistry. 2001; 276(19):
16464–16468.
[14] Aza-Blanc P, Cooper CL, Wagner K, Batalov S, Deveraux QL,
Cooke MP. Identiﬁcation of modulators of TRAIL-induced
apoptosis via RNAi-based phenotypic screening. Molecular
Cell. 2003;12(3):627–637.
[15] MacKeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen
of human kinases and phosphatases identiﬁes new regulators
of apoptosis and chemoresistance. Nature Cell Biology. 2005;
7(6):591–600.
[16] Paddison PJ, Silva JM, Conklin DS, et al. A resource for large-
scale RNA-interference-based screens in mammals. Nature.
2004; 428(6981):427–431.
[17] Berns K, Hijmans EM, Mullenders J, et al. A large-scale RNAi
screen in human cells identiﬁes new components of the p53
pathway. Nature. 2004;428(6981):431–437.
[18] Silva JM, Li MZ, Chang K, et al. Second-generation shRNA
libraries covering the mouse and human genomes. Nature Ge-
netics. 2005;37(11):1281–1288.
[19] Dickins RA, Hemann MT, Zilfou JT, et al. Probing tumor phe-
notypes using stable and regulated synthetic microRNA pre-
cursors. Nature Genetics. 2005;37(11):1289–1295.
[20] Kolfschoten IGM, van Leeuwen B, Berns K, et al. A genetic
screen identiﬁes PITX1 as a suppressor of RAS activity and tu-
morigenicity. Cell. 2005;121(6):849–858.
[21] Westbrook TF, Martin ES, Schlabach MR, et al. A genetic
screen for candidate tumor suppressors identiﬁes REST. Cell.
2005;121(6):837–848.
[22] Voorhoeve PM, Agami R. The tumor-suppressive functions of
the human INK4A locus. Cancer Cell. 2003;4(4):311–319.
[23] Zhao JJ, Gjoerup OV, Subramanian RR, et al. Human mam-
mary epithelial cell transformation through the activation
of phosphatidylinositol 3-kinase. Cancer Cell. 2003;3(5):483–
495.
[24] Jackson AL, Bartz SR, Schelter J, et al. Expression proﬁling re-
vealsoﬀ-targetgeneregulationbyRNAi.NatureBiotechnology.
2003;21(6):635–637.
[25] Lu J, Getz G, Miska EA, et al. MicroRNA expression proﬁles
classify human cancers. Nature. 2005;435(7043):834–838.
[26] Calin GA, Ferracin M, Cimmino A, et al. A microRNA sig-
nature associated with prognosis and progression in chronic
lymphocyticleukemia.NewEnglandJournalofMedicine.2005;
353(17):1793–1801.
[27] Iorio MV, Ferracin M, Liu C-G, et al. MicroRNA gene expres-
sion deregulation in human breast cancer. Cancer Research.
2005; 65(16):7065–7070.
[28] He H, Jazdzewski K, Li W, et al. The role of microRNA genes
in papillary thyroid carcinoma. Proceedings of the National
Academy of Sciences of the United States of America. 2005;
102(52): 19075–19080.
[29] deFranciscisV,CerchiaL.Aptamer-basedtechnologiesasnew
tools for proteomics in diagnosis and therapy. In: Caldwell
GW, Rahman AU, D’Andrea M, Choudhary MI, eds. Frontiers
in Drug Design & Discovery. Vol 2. Ewing Township, NJ: Ben-
tham Science; 2006:103–119.
[30] Petach H, Ostroﬀ R, Greef C, Husar GM. Processing of pho-
toaptamer microarrays. Methods in Molecular Biology. 2004;
264:101–110.
[31] Gander TR, Brody EN. Photoaptamer chips for clinical diag-
nostics. Expert Review of Molecular Diagnostics.2005;5(1):1–3.
[32] Golden MC, Collins BD, Willis MC, Koch TH. Diagnostic po-
tential of PhotoSELEX-evolved ssDNA aptamers. Journal of
Biotechnology. 2000;81(2-3):167–178.
[33] Bock C, Coleman M, Collins B, et al. Photoaptamer arrays
applied to multiplexed proteomic analysis. Proteomics. 2004;
4(3): 609–618.